New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 28, 2022 - Genentech announced that it is voluntarily withdrawing the indication for Tecentriq (atezolizumab).
Download PDF
Return to publications
